Shares of Aura Biosciences (NASDAQ:AURA) fell more than 20% during Monday’s trading session. This can be attributed to news of the company’s trial results for belzupacap sarotalocan, its eye cancer candidate.
The patients in the study saw an almost 89% tumor control rate. Indeed, the slowdown in tumor growth rate was statistically significant. Nonetheless, an unrelated adverse event caused one patient to stop the trial.
Is AURA Stock a Buy?
Turning to Wall Street, AURA stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average Aura stock price target of $28 implies 93.5% upside potential.
